Jeff Sharman, MDMedical Director of Hematology
John Pagel, MD, PhDChief of Hematologic Malignancies
Selecting the optimal treatment for patients with chronic lymphocytic leukemia (CLL) has depended, at least partly, on whether less-favorable genetic aberrations are present. Recent results from several clinical trials of new therapeutic options targeting Burton tyrosine kinase, B-cell leukemia/lymphoma 2, and phosphatidylinositol 4, 5-bisphosphate 3-kinase catalytic subunit delta has shown better outcomes, more favorable progression-free survival rates, and potentially improved tolerability for patients with and without high-risk genetic aberrations. Data from ASCO 2021 has added to our knowledge of these therapies for CLL and will be discussed in this engaging webinar.
*Review the results of recently approved and novel agents under investigation for the treatment of CLL
*Integrate new data into the development of treatment plans for CLL
The content for this program has been independently developed by Clinical Care Solutions.